|
Travoprost
(trav' oh prost).
[1R-[1 Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[( » Travoprost contains not less than 96.0 percent and not more than 102.0 percent of C26H35F3O6, calculated on the anhydrous and solvent-free basis.
[CautionGreat care should be taken to avoid contact with the body.
]
Packaging and storage
Preserve at 25
Identification
A: Thin-Layer Chromatographic Identification Test
Test solution
Use the Assay preparation.
Standard solution
Use USP Travoprost RS.
Developing solvent system:
a mixture of ethyl acetate and ethanol (4:1).
Spray reagent:
20% solution of phosphomolybdic acid in ethanol.
Procedure
Separately apply 5 µL each of the Test solution and the Standard solution to a thin-layer chromatographic plate (see Chromatography
B:
The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Specific rotation
Test solution:
20 mg per mL, in dehydrated alcohol.
Water, Method Ia
Limit of ethyl acetate
Standard solution
Dilute an accurately measured quantity of ethyl acetate in N,N-dimethylacetamide to obtain a solution having a known concentration of about 50 µg per mL.
Test solution
Dissolve an accurately weighed quantity of Travoprost in N,N-dimethylacetamide to obtain a solution having a concentration of about 20 mg per mL.
Chromatographic system (see Chromatography
Procedure
Separately inject equal volumes (about 1 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the concentration, in ppm, of ethyl acetate in the portion of Travoprost taken by the formula:
(CS / CU) (rU / rS)
in which CS is the concentration, in µg per mL, of ethyl acetate in the Standard solution; CU is the concentration, in g per mL, of Travoprost in the Test solution; and rU and rS are the peak responses obtained from the Test solution and the Standard solution, respectively; not more than 5000 ppm of ethyl acetate is found.
Related compounds
Buffer, Mobile phase, Standard preparation, and Chromatographic system
Proceed as directed in the Assay.
Test solution
Use the Assay preparation.
Procedure
Inject a volume (about 100 µL) of the Test solution into the chromatograph, record the chromatogram, and measure the peak responses. Calculate the percentage of each impurity in the portion of Travoprost taken by the formula:
100(1/F)(ri / rs)
in which F is the relative response factor for each impurity; ri is the individual peak response of each individual impurity; and rs is the sum of the responses of all the peaks. In addition to not exceeding the limits for each impurity in Table 1, not more than 0.1% of any other individual impurity is found, and not more than 4.0% of total impurities is found.
Table 1
Assay
Buffer
Add 2.0 mL of phosphoric acid to 1 L of water. Adjust with sodium hydroxide to a pH of 3.0.
Mobile phase
Prepare a filtered and degassed mixture of Buffer and acetonitrile (7:3). Make adjustments if necessary (see System Suitability under Chromatography
Standard preparation
Use USP Travopost RS without dilution (0.5 mg per mL).
Assay preparation
Transfer about 25 mg of Travoprost, accurately weighed, to a 50-mL volumetric flask, and dissolve in 15 mL of acetonitrile. Add 25 mL of water, mix, and wait until the solution reaches room temperature. Dilute with water to volume, and mix.
Chromatographic system (see Chromatography
Procedure
Separately inject equal volumes (about 100 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the percentage of C26H35F3O6 in the portion of Travoprost taken by the formula:
100(CS / CU)(rU / rS)
in which CS is the concentration, in mg per mL, of travoprost in the Standard preparation; CU is the concentration of Travoprost in the Assay preparation; and rU and rS are the peak areas obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 4915
Pharmacopeial Forum: Volume No. 32(4) Page 1115
| |||||||||||||||||||||||||||||||||||||